The Current Advances of LncRNAs in Breast Cancer Immunobiology Research

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jun 21

PMID 37342324

Authors

Marco Antonio Fonseca-Montano

Karla Itzel Vazquez-Santillan

Alfredo Hidalgo-Miranda

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most frequently diagnosed malignancy and the leading cause of cancer-related death in women worldwide. Breast cancer development and progression are mainly associated with tumor-intrinsic alterations in diverse genes and signaling pathways and with tumor-extrinsic dysregulations linked to the tumor immune microenvironment. Significantly, abnormal expression of lncRNAs affects the tumor immune microenvironment characteristics and modulates the behavior of different cancer types, including breast cancer. In this review, we provide the current advances about the role of lncRNAs as tumor-intrinsic and tumor-extrinsic modulators of the antitumoral immune response and the immune microenvironment in breast cancer, as well as lncRNAs which are potential biomarkers of tumor immune microenvironment and clinicopathological characteristics in patients, suggesting that lncRNAs are potential targets for immunotherapy in breast cancer.

Citing Articles

LncRNA-miRNA-mRNA regulatory axes as potential biomarkers in cervical cancer: a comprehensive overview.

Patel D, Thankachan S, Sreeram S, Kavitha K, Kabekkodu S, Suresh P Mol Biol Rep. 2025; 52(1):110.

PMID: 39775991 DOI: 10.1007/s11033-024-10215-2.

PCAT19: the role in cancer pathogenesis and beyond.

Hu H, Luo H, Deng Z Front Cell Dev Biol. 2025; 12:1435717.

PMID: 39744012 PMC: 11688190. DOI: 10.3389/fcell.2024.1435717.

The role of ceRNAs in breast cancer microenvironmental regulation and therapeutic implications.

Yilmaz A, Ari Yuka S J Mol Med (Berl). 2024; 103(1):33-49.

PMID: 39641797 DOI: 10.1007/s00109-024-02503-y.

Advanced Insights into Competitive Endogenous RNAs (ceRNAs) Regulated Pathogenic Mechanisms in Metastatic Triple-Negative Breast Cancer (mTNBC).

Qattan A, Al-Tweigeri T, Suleman K, Alkhayal W, Tulbah A Cancers (Basel). 2024; 16(17).

PMID: 39272915 PMC: 11394539. DOI: 10.3390/cancers16173057.

Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review.

Arshi A, Mahmoudi E, Raeisi F, Dehghan Tezerjani M, Bahramian E, Ahmed Y Front Immunol. 2024; 15:1446937.

PMID: 39257589 PMC: 11384988. DOI: 10.3389/fimmu.2024.1446937.

References

Zhou S, Liu S, Zhao L, Sun H . A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets. Front Oncol. 2022; 12:786438. PMC: 8978336. DOI: 10.3389/fonc.2022.786438. View

Degnim A, Hoskin T, Arshad M, Frost M, Winham S, Brahmbhatt R . Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development. Clin Cancer Res. 2017; 23(14):3945-3952. DOI: 10.1158/1078-0432.CCR-16-2026. View

Salemme V, Centonze G, Cavallo F, Defilippi P, Conti L . The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Front Oncol. 2021; 11:610303. PMC: 7991834. DOI: 10.3389/fonc.2021.610303. View

Amer H, Eissa R, El Tayebi H . A cutting-edge immunomodulatory interlinkage between HOTAIR and MALAT1 in tumor-associated macrophages in breast cancer: A personalized immunotherapeutic approach. Front Mol Biosci. 2022; 9:1032517. PMC: 9649622. DOI: 10.3389/fmolb.2022.1032517. View

Zhou L, Tian Y, Guo F, Yu B, Li J, Xu H . LincRNA-p21 knockdown reversed tumor-associated macrophages function by promoting MDM2 to antagonize* p53 activation and alleviate breast cancer development. Cancer Immunol Immunother. 2020; 69(5):835-846. PMC: 11027865. DOI: 10.1007/s00262-020-02511-0. View

Zhang M, Wang N, Song P, Fu Y, Ren Y, Li Z . LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1. Cell Prolif. 2020; 53(9):e12855. PMC: 7507373. DOI: 10.1111/cpr.12855. View

Li H, Liu H, Hao Q, Liu X, Yao Y, Cao M . Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer. Front Immunol. 2022; 13:891175. PMC: 9386474. DOI: 10.3389/fimmu.2022.891175. View

Zhang Q, Xiu B, Zhang L, Chen M, Chi W, Li L . Immunosuppressive lncRNA LINC00624 promotes tumor progression and therapy resistance through ADAR1 stabilization. J Immunother Cancer. 2022; 10(10). PMC: 9577936. DOI: 10.1136/jitc-2022-004666. View

Ortega M, Fraile-Martinez O, Asunsolo A, Bujan J, Garcia-Honduvilla N, Coca S . Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR. J Oncol. 2020; 2020:9258396. PMC: 7085392. DOI: 10.1155/2020/9258396. View

10.

de Santiago P, Blanco A, Morales F, Marcelain K, Harismendy O, Sjoberg Herrera M . Immune-related IncRNA LINC00944 responds to variations in ADAR1 levels and it is associated with breast cancer prognosis. Life Sci. 2020; 268:118956. DOI: 10.1016/j.lfs.2020.118956. View

11.

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

12.

Yu Y, Zhang W, Li A, Chen Y, Ou Q, He Z . Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer. JAMA Netw Open. 2020; 3(4):e202149. PMC: 7139278. DOI: 10.1001/jamanetworkopen.2020.2149. View

13.

Li S, Sun X, Li J, Zheng A, Cao Y, Guo Y . A Novel Prognostic Signature of Immune-Related Long Noncoding RNA Pairs for Tumor-Infiltrating Immune Cells and Drug Susceptibility in Breast Cancer. DNA Cell Biol. 2021; 41(2):103-115. DOI: 10.1089/dna.2021.0489. View

14.

Chen F, Chen J, Yang L, Liu J, Zhang X, Zhang Y . Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat Cell Biol. 2019; 21(4):498-510. DOI: 10.1038/s41556-019-0299-0. View

15.

Zhang S, Hu Z, Long J, Zhu G, Wang Y, Jia Y . Clinical Implications of Tumor-Infiltrating Immune Cells in Breast Cancer. J Cancer. 2019; 10(24):6175-6184. PMC: 6856577. DOI: 10.7150/jca.35901. View

16.

Dang Q, Sun Z, Wang Y, Wang L, Liu Z, Han X . Ferroptosis: a double-edged sword mediating immune tolerance of cancer. Cell Death Dis. 2022; 13(11):925. PMC: 9637147. DOI: 10.1038/s41419-022-05384-6. View

17.

Luo Z, Nong B, Ma Y, Fang D . Autophagy related long non-coding RNA and breast cancer prognosis analysis and prognostic risk model establishment. Ann Transl Med. 2022; 10(2):58. PMC: 8848359. DOI: 10.21037/atm-21-6251. View

18.

Lai J, Chen B, Zhang G, Li X, Mok H, Liao N . Molecular characterization of breast cancer: a potential novel immune-related lncRNAs signature. J Transl Med. 2020; 18(1):416. PMC: 7648293. DOI: 10.1186/s12967-020-02578-4. View

19.

Zhao S, Zhang X, Chen S, Zhang S . Long noncoding RNAs: fine-tuners hidden in the cancer signaling network. Cell Death Discov. 2021; 7(1):283. PMC: 8505617. DOI: 10.1038/s41420-021-00678-8. View

20.

Liu Z, Mi M, Li X, Zheng X, Wu G, Zhang L . A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer. J Cell Mol Med. 2020; 24(21):12444-12456. PMC: 7687003. DOI: 10.1111/jcmm.15762. View